AMRN logo

AMRN
Amarin Corp - ADR

30,433
Mkt Cap
$302.32M
Volume
29,040.00
52W High
$20.90
52W Low
$11.27
PE Ratio
-8.89
AMRN Fundamentals
Price
$14.60
Prev Close
$14.41
Open
$14.42
50D MA
$14.55
Beta
1.01
Avg. Volume
67,538.46
EPS (Annual)
-$1.87
P/B
0.67
Rev/Employee
$2.68M
$7.15
Loading...
Loading...
News
all
press releases
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy
AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.
Zacks
News Placeholder
More News
News Placeholder
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.
Zacks
News Placeholder
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
Zacks
News Placeholder
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Zacks
News Placeholder
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
Zacks
News Placeholder
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Zacks
News Placeholder
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Zacks
News Placeholder
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Zacks
News Placeholder
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
Zacks
News Placeholder
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
Zacks
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available